Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib as salvage treatment for cisplatin-resistant germ cell tumor
2014-005095-28Phase 2Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in germ cell tumor (GCT), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Preliminary antitumor activity. Started Mar 2016; status: completed.
02
Drugs
olaparib
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on 2014-005095-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005095-28.